Equillium, Inc. – NASDAQ:EQ
Founder-led company
Equillium stock price today
$1.27
+0.57
+83%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 15 hours
Equillium stock price monthly change
-17.61%
month
Equillium stock price quarterly change
-17.61%
quarter
Equillium stock price yearly change
+6.59%
year
Equillium key metrics
Market Cap | 21.43M |
Enterprise value | N/A |
P/E | -0.4 |
EV/Sales | -2.28 |
EV/EBITDA | 0.58 |
Price/Sales | 1.57 |
Price/Book | 0.77 |
PEG ratio | 0.01 |
EPS | -0.35 |
Revenue | 37.89M |
EBITDA | -12.15M |
Income | -12.12M |
Revenue Q/Q | 20.38% |
Revenue Y/Y | 53.80% |
Profit margin | -396.14% |
Oper. margin | -247.65% |
Gross margin | 100% |
EBIT margin | -247.65% |
EBITDA margin | -32.07% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeEquillium stock price history
Equillium stock forecast
Equillium financial statements
| Jun 2023 | 9.12M | -3.34M | -36.64% |
|---|---|---|---|
| Sep 2023 | 8.87M | -3.71M | -41.83% |
| Dec 2023 | 9.21M | -2.34M | -25.43% |
| Mar 2024 | 10.68M | -2.73M | -25.58% |
| Mar 2024 | 10.68M | -2.73M | -25.58% |
|---|---|---|---|
| Sep 2025 | 13.61M | -7.03M | -51.65% |
| Oct 2025 | 14.93M | -7.05M | -47.2% |
| Dec 2025 | 15.79M | -7.40M | -46.87% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 58764000 | 31.78M | 54.09% |
|---|---|---|---|
| Sep 2023 | 55225000 | 31.11M | 56.35% |
| Dec 2023 | 50530000 | 27.95M | 55.33% |
| Mar 2024 | 43597000 | 22.50M | 51.62% |
| Jun 2023 | -6.21M | 15M | -7.61M |
|---|---|---|---|
| Sep 2023 | -1.90M | 10.98M | -260K |
| Dec 2023 | -5.66M | -5.56M | 79K |
| Mar 2024 | -8.8M | -2.83M | 0 |
Equillium alternative data
| Aug 2023 | 37 |
|---|---|
| Sep 2023 | 47 |
| Oct 2023 | 47 |
| Nov 2023 | 47 |
| Dec 2023 | 45 |
| Jan 2024 | 45 |
| Feb 2024 | 45 |
| Mar 2024 | 44 |
| Apr 2024 | 44 |
| May 2024 | 44 |
| Jun 2024 | 44 |
| Jul 2024 | 44 |
Equillium other data
22.49%
-13.07%
of EQ is owned by hedge funds
16
-15
7.58M
-4.62M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Sep 2021 | 0 | 8000 |
| Oct 2021 | 0 | 2467 |
| Nov 2021 | 0 | 11434 |
| Dec 2021 | 0 | 5000 |
| Apr 2022 | 0 | 8000 |
| Jun 2022 | 0 | 5000 |
| Aug 2022 | 0 | 7000 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | KEYES JASON A officer: Chief Financial Officer | Common Stock | 7,000 | $2.83 | $19,810 | ||
Sale | KEYES JASON A officer: Chief Financial Officer | Common Stock | 5,000 | $2.52 | $12,600 | ||
Sale | KEYES JASON A officer: Chief Financial Officer | Common Stock | 8,000 | $3.18 | $25,440 | ||
Sale | KEYES JASON A officer: Chief Financial Officer | Common Stock | 5,000 | $5.08 | $25,400 | ||
Option | ZEDELMAYER CHRISTINE officer: Sr. Vice President and.. | Employee Stock Option | 23,334 | $2.45 | $57,168 | ||
Sale | ZEDELMAYER CHRISTINE officer: Sr. Vice President and.. | Common Stock | 11,434 | $5.49 | $62,715 | ||
Option | ZEDELMAYER CHRISTINE officer: Sr. Vice President and.. | Common Stock | 23,334 | $2.45 | $57,168 | ||
Option | CONNELLY STEPHEN director, officer.. | Employee Stock Option (right to buy) | 2,467 | $2.8 | $6,908 | ||
Option | CONNELLY STEPHEN director, officer.. | Common Stock | 8,092 | $3.78 | $30,547 | ||
Sale | CONNELLY STEPHEN director, officer.. | Common Stock | 2,467 | $7.01 | $17,289 |
| Quarter | Transcript |
|---|---|
| Q1 2009 7 May 2009 | Q1 2009 Earnings Call Transcript |
| Q4 2008 13 Feb 2009 | Q4 2008 Earnings Call Transcript |
| Q2 2008 30 Jul 2008 | Q2 2008 Earnings Call Transcript |
| Q1 2008 30 Apr 2008 | Q1 2008 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Krishna R. Polu (1973) Consultant | $612,000 |
| Dr. Stephen Connelly Ph.D. (1982) Chief Scientific Officer & Director | $516,610 |
Mr. Bruce D. Steel C.F.A. (1966) Co-Founder, Pres, Chief Executive Officer & Director | $414,420 |
| Mr. Daniel Mark Bradbury (1961) Executive Chairman | $92,190 |
-
What's the price of Equillium stock today?
One share of Equillium stock can currently be purchased for approximately $1.27.
-
When is Equillium's next earnings date?
Unfortunately, Equillium's (EQ) next earnings date is currently unknown.
-
Does Equillium pay dividends?
No, Equillium does not pay dividends.
-
How much money does Equillium make?
Equillium has a market capitalization of 21.43M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 128.97% to 36.08M US dollars.
-
What is Equillium's stock symbol?
Equillium, Inc. is traded on the NASDAQ under the ticker symbol "EQ".
-
What is Equillium's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Equillium?
Shares of Equillium can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Equillium's key executives?
Equillium's management team includes the following people:
- Dr. Krishna R. Polu Consultant(age: 52, pay: $612,000)
- Dr. Stephen Connelly Ph.D. Chief Scientific Officer & Director(age: 43, pay: $516,610)
- Mr. Bruce D. Steel C.F.A. Co-Founder, Pres, Chief Executive Officer & Director(age: 59, pay: $414,420)
- Mr. Daniel Mark Bradbury Executive Chairman(age: 64, pay: $92,190)
-
Is Equillium founder-led company?
Yes, Equillium is a company led by its founder Mr. Bruce D. Steel C.F.A..
-
How many employees does Equillium have?
As Jul 2024, Equillium employs 44 workers.
-
When Equillium went public?
Equillium, Inc. is publicly traded company for more then 6 years since IPO on 12 Oct 2018.
-
What is Equillium's official website?
The official website for Equillium is equilliumbio.com.
-
Where are Equillium's headquarters?
Equillium is headquartered at 2223 Avenida De La Playa, La Jolla, CA.
-
How can i contact Equillium?
Equillium's mailing address is 2223 Avenida De La Playa, La Jolla, CA and company can be reached via phone at 858 412 5302.
Equillium company profile:
Equillium, Inc.
equilliumbio.comExchange:
NASDAQ
Full time employees:
45
Industry:
Biotechnology
Sector:
Healthcare
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
2223 Avenida De La Playa
La Jolla, CA 92037
La Jolla, CA 92037
CIK: 0001746466
ISIN: US29446K1060
CUSIP: 29446K106
